2.68 USD
-0.09 (-3.25%)
We assign a fundamental rating of 5 out of 10 to BTMD. BTMD was compared to 192 industry peers in the Pharmaceuticals industry. BTMD has only an average score on both its financial health and profitability. BTMD scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
BTMD had positive earnings in the past year.
In the past year BTMD had a positive cash flow from operations.
BTMD had positive earnings in 4 of the past 5 years.
Of the past 5 years BTMD 4 years had a positive operating cash flow.
1.2 Ratios
BTMD's Return On Assets of 25.87% is amongst the best of the industry. BTMD outperforms 98.44% of its industry peers.
With an excellent Return On Invested Capital value of 45.22%, BTMD belongs to the best of the industry, outperforming 99.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.87% | ||
| ROE | N/A | ||
| ROIC | 45.22% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BTMD has a better Profit Margin (14.72%) than 86.98% of its industry peers.
BTMD's Profit Margin has declined in the last couple of years.
BTMD's Operating Margin of 16.09% is amongst the best of the industry. BTMD outperforms 85.94% of its industry peers.
In the last couple of years the Operating Margin of BTMD has declined.
BTMD has a Gross Margin of 72.23%. This is in the better half of the industry: BTMD outperforms 79.17% of its industry peers.
In the last couple of years the Gross Margin of BTMD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.09% | ||
| PM (TTM) | 14.72% | ||
| GM | 72.23% |
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BTMD is creating value.
BTMD has less shares outstanding than it did 1 year ago.
The debt/assets ratio for BTMD is higher compared to a year ago.
2.2 Solvency
BTMD has an Altman-Z score of 2.31. This is not the best score and indicates that BTMD is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of BTMD (2.31) is comparable to the rest of the industry.
The Debt to FCF ratio of BTMD is 4.18, which is a neutral value as it means it would take BTMD, 4.18 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.18, BTMD belongs to the top of the industry, outperforming 83.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.18 | ||
| Altman-Z | 2.31 |
ROIC/WACC4.84
WACC9.35%
2.3 Liquidity
A Current Ratio of 1.01 indicates that BTMD should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.01, BTMD is doing worse than 83.85% of the companies in the same industry.
A Quick Ratio of 0.72 indicates that BTMD may have some problems paying its short term obligations.
With a Quick ratio value of 0.72, BTMD is not doing good in the industry: 85.42% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.72 |
3. Growth
3.1 Past
BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 190.00%, which is quite impressive.
BTMD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -48.53% yearly.
BTMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -18.44%.
BTMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.38% yearly.
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
3.2 Future
The Earnings Per Share is expected to grow by 41.42% on average over the next years. This is a very strong growth
BTMD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.89% yearly.
EPS Next Y229.18%
EPS Next 2Y9.09%
EPS Next 3Y9.09%
EPS Next 5Y41.42%
Revenue Next Year-3.44%
Revenue Next 2Y-0.37%
Revenue Next 3Y2.36%
Revenue Next 5Y6.89%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 3.08, the valuation of BTMD can be described as very cheap.
97.92% of the companies in the same industry are more expensive than BTMD, based on the Price/Earnings ratio.
BTMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.57.
BTMD is valuated reasonably with a Price/Forward Earnings ratio of 10.24.
BTMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 86.98% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.04, BTMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.08 | ||
| Fwd PE | 10.24 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 93.75% of the companies listed in the same industry.
BTMD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BTMD is cheaper than 98.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.56 | ||
| EV/EBITDA | 6.85 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BTMD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y9.09%
EPS Next 3Y9.09%
5. Dividend
5.1 Amount
BTMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:BTMD (12/26/2025, 8:00:02 PM)
2.68
-0.09 (-3.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners63.13%
Inst Owner Change-8.25%
Ins Owners10.06%
Ins Owner Change0%
Market Cap122.37M
Revenue(TTM)195.65M
Net Income(TTM)28.79M
Analysts81.82
Price Target5.2 (94.03%)
Short Float %3.78%
Short Ratio8.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)270.4%
Min EPS beat(2)178.65%
Max EPS beat(2)362.15%
EPS beat(4)3
Avg EPS beat(4)249.23%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)105.05%
EPS beat(12)7
Avg EPS beat(12)16.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.43%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-1.55%
Revenue beat(4)1
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.65%
Revenue beat(12)4
Avg Revenue beat(12)-1.32%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.74%
PT rev (3m)-5.74%
EPS NQ rev (1m)-23.08%
EPS NQ rev (3m)-11.77%
EPS NY rev (1m)23.48%
EPS NY rev (3m)23.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.82%
Revenue NY rev (1m)-0.52%
Revenue NY rev (3m)-0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.08 | ||
| Fwd PE | 10.24 | ||
| P/S | 0.63 | ||
| P/FCF | 3.56 | ||
| P/OCF | 3.06 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.85 |
EPS(TTM)0.87
EY32.46%
EPS(NY)0.26
Fwd EY9.77%
FCF(TTM)0.75
FCFY28.12%
OCF(TTM)0.88
OCFY32.68%
SpS4.28
BVpS-1.59
TBVpS-1.9
PEG (NY)0.01
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.87% | ||
| ROE | N/A | ||
| ROCE | 57.24% | ||
| ROIC | 45.22% | ||
| ROICexc | 92.24% | ||
| ROICexgc | 190.38% | ||
| OM | 16.09% | ||
| PM (TTM) | 14.72% | ||
| GM | 72.23% | ||
| FCFM | 17.59% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score7
Asset Turnover1.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.18 | ||
| Debt/EBITDA | 3.02 | ||
| Cap/Depr | 144.67% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 3.81 | ||
| Cash Conversion | 113.15% | ||
| Profit Quality | 119.51% | ||
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 2.31 |
F-Score7
WACC9.35%
ROIC/WACC4.84
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
EPS Next Y229.18%
EPS Next 2Y9.09%
EPS Next 3Y9.09%
EPS Next 5Y41.42%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
Revenue Next Year-3.44%
Revenue Next 2Y-0.37%
Revenue Next 3Y2.36%
Revenue Next 5Y6.89%
EBIT growth 1Y-29.68%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year30.98%
EBIT Next 3Y13.56%
EBIT Next 5Y13.39%
FCF growth 1Y43.63%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y53.94%
OCF growth 3Y10.29%
OCF growth 5Y12.28%
BIOTE CORP -A / BTMD FAQ
Can you provide the ChartMill fundamental rating for BIOTE CORP -A?
ChartMill assigns a fundamental rating of 5 / 10 to BTMD.
What is the valuation status of BIOTE CORP -A (BTMD) stock?
ChartMill assigns a valuation rating of 9 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.
Can you provide the profitability details for BIOTE CORP -A?
BIOTE CORP -A (BTMD) has a profitability rating of 6 / 10.
What is the expected EPS growth for BIOTE CORP -A (BTMD) stock?
The Earnings per Share (EPS) of BIOTE CORP -A (BTMD) is expected to grow by 229.18% in the next year.
Can you provide the dividend sustainability for BTMD stock?
The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.